Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway

Jin,Zixuan; Feng,Wei; Ji,Ying; Jin,Longyu

doi:10.3892/ol.2016.5391

Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway

Authors:
- Zixuan Jin
- Wei Feng
- Ying Ji
- Longyu Jin
View Affiliations

Affiliations: Department of Biochemistry, The High School Attached To Hunan Normal University, Changsha, Hunan 410006, P.R. China, Department of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: November 17, 2016 https://doi.org/10.3892/ol.2016.5391
Pages: 347-355

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol is a small polyphenol that has been intensively studied in a wide spectrum of therapeutic fields. More recently, resveratrol has been demonstrated to exert its antitumor activity in numerous tumor models. The present study reported that resveratrol exhibited a marked anti‑proliferative effect on human esophageal squamous cell carcinoma (ESCC) cells by inducing cell cycle G0/G1 phase arrest and cell death, which was associated with a decrease in the expression levels of cyclin D1 and an increase in cleaved PARP/cleaved caspase‑3 expression levels. The mechanisms underlying the antitumor potency of resveratrol were principally attributed to the downregulation of epidermal growth factor receptor (EGFR) signaling. The western blotting results showed that exposure of ESCC cells to resveratrol inhibited EGF‑induced EGFR activation in addition to decreasing the total protein levels of EGFR and membrane/nuclear localization. In summary, the results suggested that resveratrol, or an associated analog, may have a role in the management of human ESCC.

View Figures

View References

1	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
2	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3	Hongo M, Nagasaki Y and Shoji T: Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 24:729–735. 2009. View Article : Google Scholar : PubMed/NCBI
4	Cheung WY and Liu G: Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am. 3875–91. (viii)2009.PubMed/NCBI
5	Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, Liu Z, Zhan Q, Liu Y, Yu D, et al: Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet. 43:679–684. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D, Tong T, Wang M, Lin D, Qiao Y, et al: Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nat Genet. 45:632–638. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al: Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 46:1097–1102. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gescher A, Steward WP and Brown K: Resveratrol in the management of human cancer: How strong is the clinical evidence? Ann N Y Acad Sci. 1290:12–20. 2013. View Article : Google Scholar : PubMed/NCBI
9	Frazzi R and Tigano M: The multiple mechanisms of cell death triggered by resveratrol in lymphoma and leukemia. Int J Mol Sci. 15:4977–4993. 2014. View Article : Google Scholar : PubMed/NCBI
10	Park EJ and Pezzuto JM: The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 1852:1071–1113. 2015. View Article : Google Scholar : PubMed/NCBI
11	Novelle MG, Wahl D, Diéguez C, Bernier M and de Cabo R: Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev. 21:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
12	Singh CK, George J and Ahmad N: Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci. 1290:113–121. 2013. View Article : Google Scholar : PubMed/NCBI
13	Xue YQ, Di JM, Luo Y, Cheng KJ, Wei X and Shi Z: Resveratrol oligomers for the prevention and treatment of cancers. Oxid Med Cell Longev. 2014:7658322014.PubMed/NCBI
14	Yang X, Li X and Ren J: From French Paradox to cancer treatment: Anti-cancer activities and mechanisms of resveratrol. Anticancer Agents Med Chem. 14:806–825. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lin Y, Yngve A, Lagergren J and Lu Y: A dietary pattern rich in lignans, quercetin and resveratrol decreases the risk of oesophageal cancer. Br J Nutr. 112:2002–2009. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kulkarni SS and Cantó C: The molecular targets of resveratrol. Biochim Biophys Acta. 1852:1114–1123. 2015. View Article : Google Scholar : PubMed/NCBI
17	Singh CK, Ndiaye MA and Ahmad N: Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI
18	Britton RG, Kovoor C and Brown K: Direct molecular targets of resveratrol: Identifying key interactions to unlock complex mechanisms. Ann N Y Acad Sci. 1348:124–133. 2015. View Article : Google Scholar : PubMed/NCBI
19	Tebbutt N, Pedersen MW and Johns TG: Targeting the ERBB family in cancer: Couples therapy. Nat Rev Cancer. 13:663–673. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 118:1173–1180. 2006. View Article : Google Scholar : PubMed/NCBI
21	Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M and Lassmann S: ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. J Mol Med (Berl). 92:1209–1223. 2014. View Article : Google Scholar : PubMed/NCBI
22	Hoshino M, Fukui H, Ono Y, Sekikawa A, Ichikawa K, Tomita S, Imai Y, Imura J, Hiraishi H and Fujimori T: Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology. 74:15–21. 2007. View Article : Google Scholar : PubMed/NCBI
23	Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI
24	Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
25	Han W and Lo HW: Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
26	Kolch W and Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 10:618–629. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Yu JM, Jing SW, Guo Y, Wu YJ, Li N, Jiao WP, Wang L and Zhang YJ: Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus: A meta-analysis. Asian Pac J Cancer Prev. 15:5889–5893. 2014. View Article : Google Scholar : PubMed/NCBI
28	Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR and Walch A: Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget. 5:6620–6632. 2014. View Article : Google Scholar : PubMed/NCBI
29	Gan HK, Burgess AW, Clayton AH and Scott AM: Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 72:2924–2930. 2012. View Article : Google Scholar : PubMed/NCBI
30	Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 6:803–812. 2006. View Article : Google Scholar : PubMed/NCBI
31	Schramm L: Going Green: The role of the green tea component EGCG in chemoprevention. J Carcinog Mutagen. 4:10001422013.PubMed/NCBI
32	Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R and Palumbo R: Quercetin: A pleiotropic kinase inhibitor against cancer. Cancer Treat Res. 159:185–205. 2014. View Article : Google Scholar : PubMed/NCBI
33	Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, et al: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 4:1029–1040. 1999. View Article : Google Scholar : PubMed/NCBI
34	Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH and Lipkowitz S: cbl-b inhibits epidermal growth factor receptor signaling. Oncogene. 18:1855–1866. 1999. View Article : Google Scholar : PubMed/NCBI
35	Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
36	Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
37	Li A, Zhang C, Gao S, Chen F, Yang C, Luo R and Xiao H: TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice. Oncogene. 32:2273–2281, 2281e.1–12. 2013. View Article : Google Scholar : PubMed/NCBI
38	Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y and Osamura RY: Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: Gene amplification does not contribute to EGFR expression. Oncol Rep. 14:337–343. 2005.PubMed/NCBI
39	Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF and Hung MC: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 65:338–348. 2005.PubMed/NCBI
40	Taguchi T: Nuclear translocation of epidermal growth factor receptor and its relation to clinicopathological factors in oral squamous cell carcinomas. Kokubyo Gakkai Zasshi. 81:45–52. 2014.(In Japanese). PubMed/NCBI
41	Lo HW: Nuclear mode of the EGFR signaling network: Biology, prognostic value, and therapeutic implications. Discov Med. 10:44–51. 2010.PubMed/NCBI
42	Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q and Turkson J: A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One. 6:e196052011. View Article : Google Scholar : PubMed/NCBI
43	Dittmann K, Mayer C and Rodemann HP: Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 76:157–161. 2005. View Article : Google Scholar : PubMed/NCBI
44	Dittmann K, Mayer C, Wanner G, Kehlbach R and Rodemann HP: The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor- and DNA-dependent kinase phosphorylation. Radiother Oncol. 84:328–334. 2007. View Article : Google Scholar : PubMed/NCBI
45	Liccardi G, Hartley JA and Hochhauser D: Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 20:3496–3506. 2014. View Article : Google Scholar : PubMed/NCBI
46	Dittmann K, Mayer C, Kehlbach R and Rodemann HP: Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 7:692008. View Article : Google Scholar : PubMed/NCBI